Integra LifeSciences Holdings Corp. (IART) Updates FY14 Earnings Guidance
Integra LifeSciences Holdings Corp. (NASDAQ:IART) updated its FY14 earnings guidance on Tuesday. The company provided earnings per share guidance of $2.88-3.06 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.94, AR Network reports. The company issued revenue guidance of $920-940 million, compared to the consensus revenue estimate of $928.42 million.
On a related note, analysts at Zacks reiterated a neutral rating on shares of Integra LifeSciences Holdings Corp. in a research note on Thursday, July 3rd. They now have a $50.00 price target on the stock. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company presently has an average rating of Hold and an average target price of $51.63.
Shares of Integra LifeSciences Holdings Corp. (NASDAQ:IART) traded up 1.39% on Tuesday, hitting $48.79. The stock had a trading volume of 13,394 shares. Integra LifeSciences Holdings Corp. has a 52-week low of $37.39 and a 52-week high of $49.99. The stock has a 50-day moving average of $47.27 and a 200-day moving average of $46.34. The company’s market cap is $1.589 billion.
Integra LifeSciences Holdings Corp. (NASDAQ:IART) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.68 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.64 by $0.04. The company had revenue of $231.40 million for the quarter, compared to the consensus estimate of $229.32 million. During the same quarter in the prior year, the company posted $0.60 earnings per share. The company’s quarterly revenue was up 12.6% on a year-over-year basis. Analysts expect that Integra LifeSciences Holdings Corp. will post $2.94 EPS for the current fiscal year.
In other Integra LifeSciences Holdings Corp. news, Director Stuart Essig sold 50,800 shares of the company’s stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $47.76, for a total value of $2,426,208.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) is an integrated medical technology company.
Receive News & Ratings for Integra LifeSciences Holdings Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.